B lymphocyte subset-based stratification in primary Sjögren's syndrome: implications for lymphoma risk and personalized treatment.

IF 2.9 3区 医学 Q2 RHEUMATOLOGY
Clinical Rheumatology Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI:10.1007/s10067-025-07434-8
Xuan Qi, Doudou Zhao, Naidi Wang, Yipeng Han, Bo Huang, Ruiling Feng, Yuebo Jin, Ruoyi Wang, Xiang Lin, Jing He
{"title":"B lymphocyte subset-based stratification in primary Sjögren's syndrome: implications for lymphoma risk and personalized treatment.","authors":"Xuan Qi, Doudou Zhao, Naidi Wang, Yipeng Han, Bo Huang, Ruiling Feng, Yuebo Jin, Ruoyi Wang, Xiang Lin, Jing He","doi":"10.1007/s10067-025-07434-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to perform a detailed stratification analysis of B lymphocyte subsets in patients with primary Sjögren's syndrome (pSS) and to investigate their associations with lymphoma risk, clinical phenotypes, and disease activity.</p><p><strong>Methods: </strong>In this retrospective study, we analyzed data from 137 patients with pSS. We employed machine learning approaches, specifically principal component analysis (PCA) and k-means clustering, to examine B lymphocyte subset distributions from flow cytometry data and immunoglobulin IgG and complement (C3, C4) levels. The optimal cluster number was determined using the Elbow Method in R software. Based on these 10 variables, patients were categorized into distinct subgroups. We then comprehensively compared clinical characteristics, laboratory parameters, and disease activity indices among these identified subgroups.</p><p><strong>Results: </strong>Four distinct subgroups were identified. Cluster A exhibited a significantly higher lymphoma incidence rate of 20%, compared to 3.39% in Cluster B and 0% in Clusters C and D (p = 0.007). Cluster A also had the highest percentage of double-negative B cells (32.26 ± 17.96%) and plasma cells (2.02 ± 1.92%). ESSDAI scores indicated that disease activity was highest in Cluster A (9.00, 6.00-20.00), followed by Clusters B (7.00, 3.50-14.00), C (6.00, 1.25-17.50), and D (5.00, 1.50-9.00), respectively.</p><p><strong>Conclusion: </strong>This innovative stratification method revealed the critical role of B cell subset imbalance in the pathogenesis of pSS and provided new evidence for predicting lymphoma risk and guiding personalized treatment. Key Points • Identifying a distinct patient subgroup with elevated lymphoma risk and increased disease activity could aid in risk prediction. • Applying machine learning techniques to stratify B cell populations provides insights into pSS pathogenesis. • A proposed framework for personalized treatment approaches based on B cell subset imbalances in pSS.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2403-2412"},"PeriodicalIF":2.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07434-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to perform a detailed stratification analysis of B lymphocyte subsets in patients with primary Sjögren's syndrome (pSS) and to investigate their associations with lymphoma risk, clinical phenotypes, and disease activity.

Methods: In this retrospective study, we analyzed data from 137 patients with pSS. We employed machine learning approaches, specifically principal component analysis (PCA) and k-means clustering, to examine B lymphocyte subset distributions from flow cytometry data and immunoglobulin IgG and complement (C3, C4) levels. The optimal cluster number was determined using the Elbow Method in R software. Based on these 10 variables, patients were categorized into distinct subgroups. We then comprehensively compared clinical characteristics, laboratory parameters, and disease activity indices among these identified subgroups.

Results: Four distinct subgroups were identified. Cluster A exhibited a significantly higher lymphoma incidence rate of 20%, compared to 3.39% in Cluster B and 0% in Clusters C and D (p = 0.007). Cluster A also had the highest percentage of double-negative B cells (32.26 ± 17.96%) and plasma cells (2.02 ± 1.92%). ESSDAI scores indicated that disease activity was highest in Cluster A (9.00, 6.00-20.00), followed by Clusters B (7.00, 3.50-14.00), C (6.00, 1.25-17.50), and D (5.00, 1.50-9.00), respectively.

Conclusion: This innovative stratification method revealed the critical role of B cell subset imbalance in the pathogenesis of pSS and provided new evidence for predicting lymphoma risk and guiding personalized treatment. Key Points • Identifying a distinct patient subgroup with elevated lymphoma risk and increased disease activity could aid in risk prediction. • Applying machine learning techniques to stratify B cell populations provides insights into pSS pathogenesis. • A proposed framework for personalized treatment approaches based on B cell subset imbalances in pSS.

原发性Sjögren综合征的B淋巴细胞亚群分层:对淋巴瘤风险和个性化治疗的影响。
目的:本研究旨在对原发性Sjögren综合征(pSS)患者的B淋巴细胞亚群进行详细的分层分析,并探讨其与淋巴瘤风险、临床表型和疾病活动性的关系。方法:回顾性分析137例pSS患者的资料。我们采用机器学习方法,特别是主成分分析(PCA)和k-means聚类,从流式细胞仪数据和免疫球蛋白IgG和补体(C3, C4)水平检查B淋巴细胞亚群分布。采用R软件中的肘部法确定最优聚类数。基于这10个变量,将患者分为不同的亚组。然后,我们全面比较了这些确定的亚组的临床特征、实验室参数和疾病活动指数。结果:确定了四个不同的亚组。A组淋巴瘤发病率为20%,B组为3.39%,C组和D组为0% (p = 0.007)。A群双阴性B细胞(32.26±17.96%)和浆细胞(2.02±1.92%)比例最高。ESSDAI评分显示,疾病活动性最高的是A类(9.00,6.00-20.00),其次是B类(7.00,3.50-14.00)、C类(6.00,1.25-17.50)和D类(5.00,1.50-9.00)。结论:这种创新的分层方法揭示了B细胞亚群失衡在pSS发病机制中的关键作用,为预测淋巴瘤风险和指导个性化治疗提供了新的依据。•确定淋巴瘤风险升高和疾病活动性增加的独特患者亚组有助于风险预测。•应用机器学习技术对B细胞群进行分层,为pSS发病机制提供见解。•提出了一种基于pSS中B细胞亚群失衡的个性化治疗方法框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Rheumatology
Clinical Rheumatology 医学-风湿病学
CiteScore
6.90
自引率
2.90%
发文量
441
审稿时长
3 months
期刊介绍: Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信